BioSpace News Archive

Drug Development

Polynoma Receives Special Protocol Assessment (SPA) Agreement from the U.S. FDA for a Pivotal Phase 3 Clinical Study of Seviprotimut-L, a Melanoma Cancer Vaccine

Polynoma LLC, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on a pivotal Phase 3 clinical study of seviprotimut-L.

January 11, 2022
·
7 min read
Business

AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.

January 11, 2022
·
10 min read
Business

PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced the expansion of the company’s existing strategic collaboration with Pfizer.

January 11, 2022
·
2 min read
Business

BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer

BostonGene Corporation and WellDyne today announced a strategic partnership to improve therapeutic decision-making for cancer patients.

January 11, 2022
·
3 min read
FDA

FDA approves Cochlear Nucleus Implants for unilateral hearing loss/single-sided deafness

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval of Cochlear™ Nucleus® Implants for the treatment of unilateral hearing loss (UHL)/single-sided deafness (SSD).

January 11, 2022
·
4 min read
Business

Phanes Therapeutics announces the appointment of Vice President of Business Development

Phanes Therapeutics, Inc., an emerging leader in innovative discovery research in immuno-oncology announced that it has appointed Mr. Paul Chu, MBA, as Vice President of Business Development.

January 11, 2022
·
2 min read
FDA

Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021

Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drug approvals.

January 11, 2022
·
4 min read
Genetown

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

The Vascular Care Group, a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, announced Stephen J. Hoenig M.D. successfully completed a percutaneous femoral-popliteal artery bypass at the Leominster, Mass.

January 11, 2022
·
4 min read
3D Bioprinting Market Size to Reach USD 7.39 Billion in 2028, Says Reports And Data

Rising prevalence of chronic diseases and increasing investments in development of advanced technologies are driving market revenue growth.

January 11, 2022
·
8 min read
Urinary Incontinence Market Size to Reach USD 4.53 Billion in 2028, Says Reports And Data

Extensive research and development of different therapeutic approaches to treat urinary incontinence, advancements in cognitive and behavioral therapy, and increasing prevalence of stress urinary incontinence in women across the globe are some key factors expected to drive market growth.

January 11, 2022
·
8 min read